Type 1 diabetes (T1D), which is caused by the autoimmune destruction of insulin-secreting pancreatic beta cells, represents a high-risk category requiring COVID-19 vaccine prioritization. Although COVID-19 vaccination can lead to transient hyperglycemia (vaccination-induced hyperglycemia; ViHG), its influence on the course of the clinical remission phase of T1D (a.k.a. "honeymoon phase") is currently unknown. Recently, there has been an increasing concern that COVID-19 vaccination may trigger autoimmune phenomena. We describe the case of a 24-year-old young Italian man with T1D who received two doses of the BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine during a prolonged honeymoon phase. He experienced a transient impairment in glucose control (as evidenced by continuous glucose monitoring) that was not associated with substantial changes in stimulated C-peptide levels and islet autoantibody titers. Nonetheless, large prospective studies are needed to confirm the safety and the immunometabolic impact of the BNT162b2 vaccine in T1D patients during the honeymoon phase. Thus far, T1D patients who are going to receive COVID-19 vaccination should be warned about the possible occurrence of transient ViHG and should undergo strict postvaccination surveillance.

Infante, M., Fabbri, A., Padilla, N., Pacifici, F., Di Perna, P., Vitiello, L., et al. (2022). BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report. VACCINES, 10(7), 1096 [10.3390/vaccines10071096].

BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report

Fabbri, Andrea;Pacifici, Francesca;Feraco, Alessandra;Della-Morte, David;Uccioli, Luigi
2022-07-08

Abstract

Type 1 diabetes (T1D), which is caused by the autoimmune destruction of insulin-secreting pancreatic beta cells, represents a high-risk category requiring COVID-19 vaccine prioritization. Although COVID-19 vaccination can lead to transient hyperglycemia (vaccination-induced hyperglycemia; ViHG), its influence on the course of the clinical remission phase of T1D (a.k.a. "honeymoon phase") is currently unknown. Recently, there has been an increasing concern that COVID-19 vaccination may trigger autoimmune phenomena. We describe the case of a 24-year-old young Italian man with T1D who received two doses of the BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine during a prolonged honeymoon phase. He experienced a transient impairment in glucose control (as evidenced by continuous glucose monitoring) that was not associated with substantial changes in stimulated C-peptide levels and islet autoantibody titers. Nonetheless, large prospective studies are needed to confirm the safety and the immunometabolic impact of the BNT162b2 vaccine in T1D patients during the honeymoon phase. Thus far, T1D patients who are going to receive COVID-19 vaccination should be warned about the possible occurrence of transient ViHG and should undergo strict postvaccination surveillance.
Online ahead of print
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/13
English
Con Impact Factor ISI
C-peptide
COVID-19 vaccination-induced hyperglycemia
COVID-19 vaccine
SARS-CoV-2 BNT162b2 mRNA vaccine
T1D
autoimmunity
beta cell
clinical remission
honeymoon phase
hyperglycemia
Infante, M., Fabbri, A., Padilla, N., Pacifici, F., Di Perna, P., Vitiello, L., et al. (2022). BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report. VACCINES, 10(7), 1096 [10.3390/vaccines10071096].
Infante, M; Fabbri, A; Padilla, N; Pacifici, F; Di Perna, P; Vitiello, L; Feraco, A; Giuliano, M; Passeri, M; Caprio, M; Ricordi, C; Della-Morte, D; Uccioli, L
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Covid-19 vaccine does not impact the honeymoon phase in type 1 diabetes.pdf

accesso aperto

Licenza: Copyright dell'editore
Dimensione 2.42 MB
Formato Adobe PDF
2.42 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/304434
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact